1. Home
  2. RGEN vs CAVA Comparison

RGEN vs CAVA Comparison

Compare RGEN & CAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • CAVA
  • Stock Information
  • Founded
  • RGEN 1981
  • CAVA 2006
  • Country
  • RGEN United States
  • CAVA United States
  • Employees
  • RGEN N/A
  • CAVA N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • CAVA Restaurants
  • Sector
  • RGEN Health Care
  • CAVA Consumer Discretionary
  • Exchange
  • RGEN Nasdaq
  • CAVA Nasdaq
  • Market Cap
  • RGEN 7.6B
  • CAVA 16.2B
  • IPO Year
  • RGEN N/A
  • CAVA 2023
  • Fundamental
  • Price
  • RGEN $156.55
  • CAVA $112.43
  • Analyst Decision
  • RGEN Buy
  • CAVA Buy
  • Analyst Count
  • RGEN 12
  • CAVA 13
  • Target Price
  • RGEN $187.44
  • CAVA $142.85
  • AVG Volume (30 Days)
  • RGEN 470.1K
  • CAVA 2.2M
  • Earning Date
  • RGEN 02-19-2025
  • CAVA 02-25-2025
  • Dividend Yield
  • RGEN N/A
  • CAVA N/A
  • EPS Growth
  • RGEN N/A
  • CAVA N/A
  • EPS
  • RGEN N/A
  • CAVA 0.46
  • Revenue
  • RGEN $633,513,000.00
  • CAVA $913,488,000.00
  • Revenue This Year
  • RGEN $2.28
  • CAVA $34.56
  • Revenue Next Year
  • RGEN $9.88
  • CAVA $23.50
  • P/E Ratio
  • RGEN N/A
  • CAVA $243.55
  • Revenue Growth
  • RGEN N/A
  • CAVA 34.05
  • 52 Week Low
  • RGEN $113.50
  • CAVA $42.65
  • 52 Week High
  • RGEN $211.13
  • CAVA $172.43
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 60.07
  • CAVA 37.56
  • Support Level
  • RGEN $149.15
  • CAVA $109.23
  • Resistance Level
  • RGEN $160.64
  • CAVA $120.77
  • Average True Range (ATR)
  • RGEN 5.96
  • CAVA 3.67
  • MACD
  • RGEN 0.91
  • CAVA 0.31
  • Stochastic Oscillator
  • RGEN 79.57
  • CAVA 27.72

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About CAVA CAVA Group Inc.

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.

Share on Social Networks: